David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1101
PUT
Skyworks Solutions
SWKS
$9.89B
| $9.59M | 0.01% |
116,300
-65,300
| -36% | -$5.04M |
|
|
TYPE
1102
DELISTED
Monotype Imaging Holdings Inc.
TYPE
| $9.55M | 0.01% |
480,061
+137,836
| +40% | +$2.48M |
|
1103
CALL
MetLife
MET
$60.9B
| $9.53M | 0.01% |
223,900
+131,700
| +143% | +$5.82M |
|
|
PPL
1104
PPL Corp
PPL
$26.3B
| $9.52M | 0.01% |
300,075
-1,098,778
| -79% | -$34.2M |
|
|
WBT
1105
DELISTED
Welbilt, Inc.
WBT
| $9.52M | 0.01% |
581,395
+539,806
| +1,298% | +$7.88M |
|
|
VSTO
1106
DELISTED
Vista Outdoor Inc.
VSTO
| $9.51M | 0.01% |
1,187,247
+84,358
| +8% | +$825K |
|
1107
CBIZ
CBZ
$2.97B
| $9.5M | 0.01% |
469,337
+33,738
| +8% | +$682K |
|
|
LSI
1108
DELISTED
Life Storage, Inc.
LSI
| $9.49M | 0.01% |
146,394
+59,766
| +69% | +$3.83M |
|
1109
Toro Company
TTC
$9.48B
| $9.46M | 0.01% |
137,397
-45,391
| -25% | -$2.88M |
|
1110
Ingevity
NGVT
$2.37B
| $9.46M | 0.01% |
+89,543
| New | +$9M |
|
1111
Logitech
LOGI
$14.1B
| $9.44M | 0.01% |
239,994
+32,028
| +15% | +$1.15M |
|
1112
Wave Life Sciences
WVE
$1.03B
| $9.43M | 0.01% |
242,644
+117,353
| +94% | +$4.76M |
|
1113
Anika Therapeutics
ANIK
$286M
| $9.42M | 0.01% |
311,608
+150,115
| +93% | +$5.14M |
|
1114
Scotiabank
BNS
$113B
| $9.37M | 0.01% |
175,826
+170,127
| +2,985% | +$9.32M |
|
|
ERF
1115
DELISTED
Enerplus Corporation
ERF
| $9.34M | 0.01% |
1,113,578
+513,100
| +85% | +$4.41M |
|
1116
CALL
Regeneron Pharmaceuticals
REGN
$85.8B
| $9.32M | 0.01% |
22,700
+800
| +4% | +$329K |
|
1117
Axos Financial
AX
$5.61B
| $9.3M | 0.01% |
320,981
+119,878
| +60% | +$3.59M |
|
|
IBKC
1118
DELISTED
IBERIABANK Corp
IBKC
| $9.29M | 0.01% |
129,578
+76,862
| +146% | +$5.71M |
|
|
ICPT
1119
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $9.24M | 0.01% |
82,600
+35,300
| +75% | +$3.86M |
|
1120
Enviri
NVRI
$609M
| $9.24M | 0.01% |
458,292
+300,984
| +191% | +$6.48M |
|
1121
1-800-Flowers.com
FLWS
$251M
| $9.23M | 0.01% |
506,337
+53,885
| +12% | +$868K |
|
1122
Cincinnati Financial
CINF
$26.3B
| $9.2M | 0.01% |
107,041
-1,592
| -1% | -$131K |
|
1123
CALL
BP
BP
$110B
| $9.19M | 0.01% |
213,745
+151,323
| +242% | +$6.2M |
|
1124
Hilltop Holdings
HTH
$2.21B
| $9.15M | 0.01% |
501,438
-70,432
| -12% | -$1.31M |
|
1125
ArcBest
ARCB
$3.03B
| $9.13M | 0.01% |
296,488
+15,459
| +6% | +$558K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.